Literature DB >> 22095369

Effect of telavancin (Vibativ) on routine coagulation test results.

Robert Gosselin1, William Dager, Aaron Roberts, Leslie Freeman, Lisa Gandy, Jeffrey Gregg, Denis Dwyre.   

Abstract

Telavancin (Vibativ, Astellas Pharma US, Deerfield, IL) is a lipoglycopeptide antibiotic that has activity against gram-positive microorganisms, but also has the ability to bind to artificial phospholipids found in coagulation reagents. Normal pooled plasma was spiked with telavancin to obtain concentrations of 0, 12.5, 25, 50, 75, 100, 125, and 150 μg/mL of drug. Samples were tested using 3 different prothrombin time/international normalized ratio (INR) and activated partial thromboplastin time (aPTT) reagent systems, as well as for fibrinogen level, thrombin time, D-dimer level, dilute Russell viper venom time (DRVVT), protein C activity, and protein S activity. There was no effect of telavancin seen with non-phospholipid-dependent assays: fibrinogen level, thrombin time, and D-dimer testing. All INR and aPTT systems demonstrated concentration-dependent increases in clotting times, with Innovin (Siemens Healthcare Diagnostics, Deerfield, IL) INRs the most dramatic. False-positive DRVVT ratios started at 12.5 μg/mL of telavancin, with no effect on protein C or protein S levels until the telavancin level reached more than 100 μg/mL.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22095369     DOI: 10.1309/AJCPDPL4G7CERYJU

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  Impact of telavancin on prothrombin time and activated partial thromboplastin time as determined using point-of-care coagulometers.

Authors:  Michael P Ero; Nathaniel R Harvey; Jack L Harbert; James W Janc; Kay H Chin; Steven L Barriere
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

2.  Case report: artificial elevation of prothrombin time by telavancin.

Authors:  Derek F Amanatullah; Matthew J Lopez; Robert C Gosselin; Munish C Gupta
Journal:  Clin Orthop Relat Res       Date:  2012-11-06       Impact factor: 4.176

3.  Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.

Authors:  Adam Belley; Richard Robson; John L Francis; Dorothy M Adcock; Stefan Tiefenbacher; Christopher M Rubino; Greg Moeck; David Sylvester; Michael N Dudley; Jeffery Loutit
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

4.  Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Candace Y Hooper; Winter J Smith
Journal:  Ther Clin Risk Manag       Date:  2012-03-16       Impact factor: 2.423

5.  The effects of fructose diphosphate on routine coagulation tests in vitro.

Authors:  Tongqing Chen; Duan Chen; Lu Chen; Zhengxu Chen; Baolong Wang; Daoping Zhou
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.